人黑色素瘤細胞系M14

細胞名稱

人黑色素瘤細胞系M14

貨物編碼

BFN60808843

產品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細胞數量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運輸方式

常溫保溫運輸

干冰運輸

安全等級

1

用途限制

僅供科研   3類

培養(yǎng)體系

90%DMEM+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人黑色素瘤細胞系M14取自33歲男性供體。貼壁培養(yǎng)。

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

Doubling time: 26.3 hours (NCI-DTP).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=12068308; PubMed=17088437; PubMed=19799798; PubMed=29492214).

Heterozygous for CDKN2A c.150+2T>C (IVS1+2T>C); splice donor mutation and c.455insCdel26 (PubMed=19799798; PubMed=29492214).

Heterozygous for TP53 p.Gly266Glu (c.797G>A) (ClinVar=VCV000161516) (PubMed=17088437; PubMed=18277095).

HLA信息

Class I

HLA-A        A*11:01:01,24:02:01

HLA-B        B*15,35

HLA-C        C*03:03:01,04

Class II

HLA-DP        DPB1*13:01,19:01

HLA-DQ        DQB1*03:02,06:03

HLA-DR        DRB1*04:05:01,13:01:01

STR信息

Amelogenin        X

CSF1PO        11

D1S1656        11,12

D2S441        11,14

D2S1338        19,24

D3S1358        14,16

D5S818        11,12

D7S820        8,10

D8S1179        13

D10S1248        14

D12S391        18,19

D13S317        12

D16S539        9,13

D18S51        13,17

D19S433        14,15

D21S11        30

D22S1045        15

FGA        21

SE33        15,22

TH01        6,7

TPOX        8,11

vWA        16,18

參考文獻

PubMed=27807467; DOI=10.1186/s13100-016-0078-4

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=28940260; DOI=10.1002/ijc.31067

Korch C., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L., Kniss D., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.

Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.

Int. J. Cancer 142:561-572(2017)

PubMed=29492214; DOI=10.18632/oncotarget.23989

Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M., Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.

Genetic alterations in main candidate genes during melanoma progression.

Oncotarget 9:8531-8541(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)